Topic: Parkinson's disease
A startup from Johns Hopkins launched with $36 million to bring a potentially disease-modifying drug into phase 1 for Parkinson’s disease.
Verge Genomics raised $32 million to bring its AI-generated compounds to the clinic against ALS and Parkinson’s disease in the next three years.
Titan gets the OK to start stage two in a trial of its ropinirole implant for Parkinson’s—but has to postpone because of financial constraints.
Four months after Voyager's chief and founder said he would step down, the neurological disease biotech has found a new leader.
Appello Pharmaceuticals raised $10.5 million to fund its glutamate-modulating Parkinson’s disease treatment licensed from Vanderbilt University.
Last week’s biotech discoveries include a gut-coating pill that lowers glucose and prostate-tumor test to predict a good response to immunotherapy.
Axovant is continuing its change-up with a new focus and a new exec.
Hard on the heels of a deal with Allergan, Aptinyx unveils plans for an $80 million IPO to accelerate work on its drugs for neurological disorders.
A team of scientists clarified the role of the protein LRRK2 in tuberculosis, suspecting that it behaves similarly in Parkinson's.
With the diabetes project moving to within a few years of the clinic, Novo is stepping up its interest in stem cell therapies more broadly.